Grantable
PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate Cancer (mPC) Landscape Grant · THE PFIZER FOUNDATION INC
up to $350,000
PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate Cancer (mPC) Landscape Grant Status: ACTIVE Funder: Pfizer, Inc. Amount: Up to US $350,000 Last Updated: August 04, 2025 Summary Pfizer's c…
Welcome to Grantable
Sign in to start building your grant-ready profile
or
We'll send you a one-time verification code. No password needed. By signing in you agree to our Terms of Service and Privacy Policy.